Linezolid Fresenius Kabi (Linezolid)

• Linezolid is an oxazolidinone antibacterial indicated for several serious Gram‑positive infections.
• Complicated skin and soft tissue infections: Effective against susceptible Gram‑positive bacteria, including MRSA, when oral therapy is unsuitable.
• Community‑acquired bacterial pneumonia: Provides coverage for resistant Gram‑positive pathogens causing pneumonia.
• MRSA infections: Used to treat infections caused by methicillin‑resistant Staphylococcus aureus.
• VRE infections: Active against vancomycin‑resistant Enterococcus species.
• Other serious Gram‑positive infections: Addresses infections by resistant Gram‑positive organisms when alternative agents are limited.

• Linezolid inhibits bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit. This binding prevents formation of the initiation complex, halting translation and thereby stopping bacterial growth. The action is bacteriostatic against most susceptible organisms and is selective for bacterial ribosomes, sparing human protein synthesis pathways.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, occasionally watery.
• Headache: transient cranial discomfort.
• Metallic taste: altered taste perception during therapy.
• Thrombocytopenia: reduced platelet count, usually reversible.
• Anemia: mild decrease in hemoglobin levels.

Serious or Rare Side Effects

• Lactic acidosis: metabolic acidosis with elevated lactate, potentially life‑threatening.
• Peripheral neuropathy: sensory disturbances that may become irreversible.
• Serotonin syndrome: risk when combined with serotonergic agents, presenting with agitation, hyperreflexia, and hyperthermia.
• Severe neutropenia: marked drop in neutrophil count increasing infection risk.
• Hepatic dysfunction: elevated liver enzymes indicating possible liver injury.

• Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.
• Monitor blood counts: perform regular CBC to detect thrombocytopenia, anemia, or neutropenia.
• Assess renal function: adjust therapy if significant renal impairment is present.
• Avoid serotonergic agents: co‑administration can precipitate serotonin syndrome.
• Use cautiously in mitochondrial disorders: risk of lactic acidosis may be heightened.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

• Serotonergic agents (SSRIs, SNRIs, MAO inhibitors): risk of serotonin syndrome.
• MAO inhibitors: can cause hypertensive crisis when combined.
• Rifampin: induces metabolism, reducing linezolid plasma concentrations.
• Tyramine‑rich foods with MAO inhibition: may trigger hypertensive reactions.

Moderate Interactions (Monitor Closely)

• Warfarin: linezolid may increase INR; monitor coagulation parameters.
• Other CYP450 substrates: potential alteration of drug levels; observe therapeutic response.
• Nephrotoxic drugs: additive risk of hematologic toxicity; assess renal function and blood counts.